WallStreetZenWallStreetZen

NASDAQ: CYTK
Cytokinetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CYTK

Based on 13 analysts offering 12 month price targets for Cytokinetics Inc

Min Forecast
$69.00+3.4%
Avg Forecast
$92.23+38.22%
Max Forecast
$136.00+103.81%

Should I buy or sell CYTK stock?

Based on 13 analysts offering ratings for Cytokinetics Inc.

Strong Buy
Strong Buy
6 analysts 46.15%
Buy
6 analysts 46.15%
Hold
1 analysts 7.69%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CYTK's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CYTK as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CYTK stock forecasts and price targets.

CYTK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-18
lockedlocked$00.00+00.00%2026-03-17
lockedlocked$00.00+00.00%2026-03-06
lockedlocked$00.00+00.00%2026-02-26
lockedlocked$00.00+00.00%2026-02-25
Needham
Top 1%
100
BuyMaintains$85.00+27.38%2026-02-25
RBC Capital
Top 9%
92
BuyMaintains$101.00+51.36%2026-02-20
Truist Securities
Top 10%
91
Strong BuyMaintains$92.00+37.87%2026-02-03Find out why
Barclays
Bottom 9%
9
Strong BuyAssumes$87.00+30.38%2026-01-28
B. Riley Securities
Top 3%
98
Strong BuyMaintains$108.00+61.85%2026-01-21Find out why

1 of 2

Forecast return on equity

Is CYTK forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CYTK forecast to generate an efficient return on assets?

Company
-1.46%
Industry
31.92%
CYTK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CYTK earnings per share forecast

What is CYTK's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
-$6.69
Avg 2 year Forecast
-$4.83
Avg 3 year Forecast
-$2.41

CYTK revenue forecast

What is CYTK's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$94.1M+6.88%
Avg 2 year Forecast
$384.2M+336.34%
Avg 3 year Forecast
$873.0M+891.65%
CYTK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CYTK revenue growth forecast

How is CYTK forecast to perform vs Biotechnology companies and vs the US market?

Company
111.69%
Industry
38.82%
Market
13.79%
CYTK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CYTK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CYTK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CYTK$66.73$92.23+38.22%Strong Buy
NUVL$105.43$137.57+30.49%Strong Buy
TECH$53.13$73.71+38.74%Strong Buy
PCVX$58.38$105.00+79.86%Strong Buy
ARWR$61.03$89.75+47.06%Strong Buy
View Top Biotech Stocks

Cytokinetics Stock Forecast FAQ

Is Cytokinetics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NASDAQ: CYTK) stock is to Strong Buy CYTK stock.

Out of 13 analysts, 6 (46.15%) are recommending CYTK as a Strong Buy, 6 (46.15%) are recommending CYTK as a Buy, 1 (7.69%) are recommending CYTK as a Hold, 0 (0%) are recommending CYTK as a Sell, and 0 (0%) are recommending CYTK as a Strong Sell.

If you're new to stock investing, here's how to buy Cytokinetics stock.

What is CYTK's earnings growth forecast for 2026-2028?

(NASDAQ: CYTK) Cytokinetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.

Cytokinetics's earnings in 2026 is -$784,955,000.On average, 22 Wall Street analysts forecast CYTK's earnings for 2026 to be -$823,922,230, with the lowest CYTK earnings forecast at -$872,657,753, and the highest CYTK earnings forecast at -$734,542,981. On average, 21 Wall Street analysts forecast CYTK's earnings for 2027 to be -$594,925,623, with the lowest CYTK earnings forecast at -$704,885,377, and the highest CYTK earnings forecast at -$360,805,443.

In 2028, CYTK is forecast to generate -$296,403,611 in earnings, with the lowest earnings forecast at -$514,180,087 and the highest earnings forecast at -$183,635,745.

What is CYTK's revenue growth forecast for 2026-2028?

(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 111.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.

Cytokinetics's revenue in 2026 is $88,039,000.On average, 22 Wall Street analysts forecast CYTK's revenue for 2026 to be $11,589,004,325, with the lowest CYTK revenue forecast at $7,241,973,052, and the highest CYTK revenue forecast at $23,581,982,656. On average, 21 Wall Street analysts forecast CYTK's revenue for 2027 to be $47,312,992,309, with the lowest CYTK revenue forecast at $38,008,042,240, and the highest CYTK revenue forecast at $64,996,708,138.

In 2028, CYTK is forecast to generate $107,526,057,023 in revenue, with the lowest revenue forecast at $72,243,607,702 and the highest revenue forecast at $171,688,952,958.

What is CYTK's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CYTK) forecast ROA is -1.46%, which is lower than the forecast US Biotechnology industry average of 31.92%.

What is CYTK's Price Target?

According to 13 Wall Street analysts that have issued a 1 year CYTK price target, the average CYTK price target is $92.23, with the highest CYTK stock price forecast at $136.00 and the lowest CYTK stock price forecast at $69.00.

On average, Wall Street analysts predict that Cytokinetics's share price could reach $92.23 by Mar 18, 2027. The average Cytokinetics stock price prediction forecasts a potential upside of 38.22% from the current CYTK share price of $66.73.

What is CYTK's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CYTK) Cytokinetics's current Earnings Per Share (EPS) is -$6.54. On average, analysts forecast that CYTK's EPS will be -$6.69 for 2026, with the lowest EPS forecast at -$7.09, and the highest EPS forecast at -$5.96. On average, analysts forecast that CYTK's EPS will be -$4.83 for 2027, with the lowest EPS forecast at -$5.72, and the highest EPS forecast at -$2.93. In 2028, CYTK's EPS is forecast to hit -$2.41 (min: -$4.17, max: -$1.49).

What is CYTK's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CYTK) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.